Page 105 - Read Online

Page 10 of 12 Liu et al. Hepatoma Res 2020;6:42 I http://dx.doi.org/10.20517/2394-5079.2020.25

analysis of the current literature. BMC Cancer 2011;11:446.
20. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572-85.
21. Jean-Frédéric B, Adelaide D, Marie-Quitterie P, Aline M, Caroline B, et al. Diabetes, HBV infection and smoking are independent risk
factors for developing hepatocellular carcinoma on non-fibrotic liver in the NoFLIC French multicenter case-control study. Hepatology
2015;62:276A.
22. Costentin CE, Mourad A, Lahmek P, Causse X, Pariente A, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic
patients: results of a prospective, nationwide study. Cancer 2018;124:1964-72.
23. Bucci L, Garuti F, Camelli V, Lenzi B, Farinati F, et al.; Italian Liver Cancer (ITA.LI.CA) Group; Italian Liver Cancer ITA LI CA Group.
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.
Aliment Pharmacol Ther 2016;43:385-99.
24. Kumar R, Goh BBG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular
carcinoma. Clin Mol Hepatol 2020;26:196-208.
25. EASL. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
26. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018
practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
27. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma
in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-24.
28. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of
hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
29. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72:250-61.
30. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer
Prev Res (Phila) 2012;5:1124-30.
31. Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, et al. EASL Clinical Practice Guidelines: Management of alcohol-related liver
disease. J Hepatol 2018;69:154-81.
32. Teschke R. Alcoholic liver disease: alcohol metabolism, cascade of molecular mechanisms, cellular targets, and clinical aspects.
Biomedicines 2018;6:106.
33. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol
Chem 2006;387:349-60.
34. Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012;61:150-9.
35. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006;41:209-24.
36. Homann N, Stickel F, Konig IR, Jacobs A, Junghanns K, et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-
associated cancer in heavy drinkers. Int J Cancer 2006;118:1998-2002.
37. Seitz HK, Stickel F. Molecular mechanisms of alcohol mediated carcinogenesis. Nat Rev 2007;7:599-612.
38. Dasgupta A. Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse.
Alcohol, Drugs, Genes and the Clinical Laboratory 2017:107-16.
39. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, et al. A protein-truncating HSD17B13 variant and protection from chronic liver
disease. Engl J Med 2018;378:1096-106.
40. Buch S, Stickel F, Trepo E, Way M, Herrmann A, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and
MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015;47:1443-8.
41. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat
Genet 2010;42:21-3.
42. Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with
hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012;55:1307-8.
43. Salameh H, Raff E, Erwin A, Seth D, Nischalke HD, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity
of alcoholic liver disease. Am J Gastroenterol 2015;110:846-56.
44. Falleti E, Cussigh A, Cmet S, Fabris C, Toniutto P. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of
hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis 2016;48:69-75.
45. Seth D, Daly AK, Haber PS, Day CP. Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for
alcoholic and nonalcoholic liver disease. Hepatology 2010;51:1463-5.
46. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, et al. Association between the PNPLA3 (rs738409 C\textgreaterG) variant and
hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology 2014;59.
47. Chen JH, Wang YY, Lv WB, Gan Y, Chang W, et al. Effects of interactions between environmental factors and KIF1B genetic variants on
the risk of hepatocellular carcinoma in a Chinese cohort. World J Gastroenterol 2016;22:4183-90.
48. Nahon P, Cao Q, Guyot E, Rufat P, Sutton A, et al. O054 TM6SF2-T and PNPLA3-G genetic variants co-modulate the risk of
hepatocellular carcinoma in caucasian patients with alcoholic cirrhosis. Inter-cohort validation in 1068 patients. J Hepatol 2015;62:S218-9.
49. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, et al. Genome-wide association study identifies loci influencing concentrations of liver
enzymes in plasma. Nat Genet 2011;43:1131-8.
50. Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and
hepatocellular carcinoma in alcohol misusers. Hepatology 2019; epub ahead of print. doi: 10.1002/hep.30996
51. Thursz M, Kamath PS, Mathurin P, Szabo G, Shah VH. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities